介素-1受体对抗剂:用于癌症治疗的替代疗法
Zhang Fang1, Jingting Jiang1, Xiao Zheng1
1Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, China; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, China.
介素-1受体对抗剂 (IL-1Ra) 通过抵消炎症,在癌症治疗中表现有前途. 一种IL-1Ra药物Anakinra显示出抗瘤效果,并有可能成为未来癌症治疗的生物标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 介素-1 (IL-1) 信号传递与瘤进展有关,包括瘤的形成,生长和转移.
- 介素-1受体对抗剂 (IL-1Ra) 是一种天然的抗炎细胞因子,可以抑制IL-1信号传递.
- 美国食品和药物管理局批准的IL-1Ra,Anakinra已经显示出临床前的抗瘤活性.
研究的目的:
- 审查IL-1在癌症中的作用.
- 要总结IL-1Ra (anakinra) 对瘤免疫力的影响.
- 分析IL-1Ra作为癌症生物标志物的临床潜力.
主要方法:
- 综合文献综述. 这是一个全面的文献综述.
- 对瘤IL-1的研究进展的分析.
- 评估阿纳金拉对瘤免疫力的贡献.
- 对IL-1Ra作为生物标志物的临床观点.
主要成果:
- IL-1信号传递是瘤发展的关键因素.
- 在临床前的模型中,anakinra表现出有希望的抗瘤作用.
- IL-1Ra在调节瘤免疫力方面发挥着重要作用.
- IL-1Ra具有作为临床生物标志物的潜力.
结论:
- 炎症和癌症之间的联系至关重要.
- IL-1Ra (anakinra) 在癌症治疗中具有治疗潜力.
- 对IL-1Ra的进一步研究可以确定用于癌症治疗的新药标.
更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
